Financial report for Q1 2018
NNIT delivers an operating profit margin of 8.7% while revenue declines by 2.3% despite a revenue increase of 12% from non-Novo Nordisk customers
Performance highlights for Q1 2018
Per Kogut, CEO at NNIT says about the results for the first three months of 2018: "I am encouraged by the continued strong growth in particular the enterprise and international life sciences customer groups. The decline in revenue from the Novo Nordisk Group was larger than expected and we have therefore adjusted our revenue growth guidance for 2018 to 3-6%. Under these circumstances, I am pleased that we have maintained our operating profit margin guidance of 10-10.5%."
Conference call details
NNIT will host a teleconference May 16, 2018 at 10:30 CET about the financial report for Q1 2018. Please visit the NNIT webpage at www.nnit.com to access the teleconference, which can be found under 'Investors - Events & presentations'. Presentation material will be available on the website approximately one hour prior to the start of the presentation.
Conference call details
Participant telephone numbers:
Denmark: +45 3544 5583
United Kingdom: +44 20 3194 0544
Sweden: +46 8 5664 2661
United States: +1 855 269 2604
Financial Calendar 2018
August 17, 2018 Interim report for the first six months of 2018
August 22, 2018 Interim dividend ex dividend date
August 23, 2018 Interim dividend record date
August 24, 2018 Interim dividend payment date
October 25, 2018 Interim report for the first nine months of 2018
Contacts for further information
Investor relations:
Klaus Hosbond Skovrup
Head of Investor Relations
Tel: +45 3079 5355
ksko@nnit.com
Media relations:
Helga Heyn
NNIT Communications
Tel: +45 3077 8141
hhey@nnit.com
Attachment